NeurAxis (NRXS) Competitors $2.15 +0.04 (+1.90%) Closing price 04:00 PM EasternExtended Trading$2.16 +0.01 (+0.47%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock NRXS vs. HYPR, ICAD, CTSO, MBOT, TELA, APT, ECOR, APYX, INO, and TMDIFShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include Hyperfine (HYPR), iCAD (ICAD), Cytosorbents (CTSO), Microbot Medical (MBOT), TELA Bio (TELA), Alpha Pro Tech (APT), electroCore (ECOR), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry. NeurAxis vs. Hyperfine iCAD Cytosorbents Microbot Medical TELA Bio Alpha Pro Tech electroCore Apyx Medical Inovio Pharmaceuticals Titan Medical NeurAxis (NASDAQ:NRXS) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking. Does the MarketBeat Community favor NRXS or HYPR? Hyperfine received 5 more outperform votes than NeurAxis when rated by MarketBeat users. However, 100.00% of users gave NeurAxis an outperform vote while only 50.00% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformNeurAxisOutperform Votes1100.00% Underperform VotesNo VotesHyperfineOutperform Votes650.00% Underperform Votes650.00% Which has more volatility and risk, NRXS or HYPR? NeurAxis has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Is NRXS or HYPR more profitable? Hyperfine has a net margin of -309.42% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets NeurAxis-492.76% N/A -641.25% Hyperfine -309.42%-57.54%-50.38% Does the media refer more to NRXS or HYPR? In the previous week, NeurAxis had 1 more articles in the media than Hyperfine. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.69 beat NeurAxis' score of -0.32 indicating that Hyperfine is being referred to more favorably in the news media. Company Overall Sentiment NeurAxis Neutral Hyperfine Positive Do institutionals and insiders believe in NRXS or HYPR? 11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 15.2% of NeurAxis shares are owned by company insiders. Comparatively, 29.4% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, NRXS or HYPR? NeurAxis has higher earnings, but lower revenue than Hyperfine. NeurAxis is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurAxis$2.69M5.64-$14.63M-$1.20-1.75Hyperfine$12.89M4.52-$44.24M-$0.56-1.34 Do analysts recommend NRXS or HYPR? Hyperfine has a consensus price target of $1.33, indicating a potential upside of 77.81%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than NeurAxis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryHyperfine beats NeurAxis on 11 of the 18 factors compared between the two stocks. Remove Ads Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.15M$3.30B$5.59B$7.94BDividend YieldN/A1.64%5.35%4.04%P/E Ratio-1.1415.4723.6218.84Price / Sales5.6443.23369.8489.23Price / CashN/A44.0938.1634.64Price / Book-7.783.426.704.19Net Income-$14.63M$94.03M$3.20B$247.10M7 Day Performance-1.87%-0.91%-3.62%-2.81%1 Month Performance-3.67%-11.02%-0.26%-6.32%1 Year Performance-33.96%-19.93%9.43%0.43% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxisN/A$2.15+1.9%N/A-35.2%$15.51M$2.69M-1.1719Gap UpHigh Trading VolumeHYPRHyperfine3.5419 of 5 stars$0.83+1.2%$1.33+60.2%-30.6%$60.56M$12.89M-1.46190High Trading VolumeICADiCAD0.4498 of 5 stars$2.28+2.2%N/A+30.3%$60.51M$19.61M-17.54140CTSOCytosorbents2.0904 of 5 stars$1.03+4.7%$4.67+353.1%+10.0%$56.32M$33.79M-2.86220Earnings ReportAnalyst ForecastNews CoverageMBOTMicrobot Medical1.6477 of 5 stars$1.60-5.9%$9.00+462.5%+12.0%$55.59MN/A-2.0020Earnings ReportNews CoverageTELATELA Bio2.0842 of 5 stars$1.40-4.8%$7.25+417.9%-76.3%$55.14M$68.65M-0.83120News CoverageGap DownHigh Trading VolumeAPTAlpha Pro TechN/A$5.05+0.6%N/A-23.1%$54.91M$57.84M13.65120ECORelectroCore2.4109 of 5 stars$7.43-7.1%$25.50+243.2%+1.1%$53.44M$25.18M-4.0650High Trading VolumeAPYXApyx Medical1.9393 of 5 stars$1.38+9.5%N/A-8.8%$52.16M$48.10M-1.66270Gap UpINOInovio Pharmaceuticals3.9838 of 5 stars$1.88-2.1%$12.20+548.9%-88.6%$49.07M$217,756.00-0.47320TMDIFTitan MedicalN/A$0.43flatN/A+668.8%$49.04M$17.63M-0.3450Gap Up Remove Ads Related Companies and Tools Related Companies Hyperfine Alternatives iCAD Alternatives Cytosorbents Alternatives Microbot Medical Alternatives TELA Bio Alternatives Alpha Pro Tech Alternatives electroCore Alternatives Apyx Medical Alternatives Inovio Pharmaceuticals Alternatives Titan Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
